



Precision Oncology.
See it. Treat it.

Telix Pharmaceuticals Limited

ASX: TLX

Dr Chris Behrenbruch, Chief Executive Officer

Dr David N. Cade, Chief Business Officer

Bell Potter Healthcare Conference

26th November 2020

Disclaimer



The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (“Telix”) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation may contain forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Telix, and its directors, officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Telix’s product pipeline. Actual results from clinical trials may vary from those shown. None of the products or potential products described in this presentation have received a marketing authorization in any jurisdiction.

Company snapshot



- Comprehensive, late-stage portfolio of **Molecularly Targeted Radiation (MTR)** products
 - ✓ Prostate cancer, renal cancer, glioblastoma
 - ✓ Significant **total addressable market** value of **US\$850M** & **US\$4B** for prostate imaging and therapy, respectively
 - ✓ Clinical research activity in 25 countries, global reach
- **2020:** Achieved major **commercialisation** milestones for TLX591-CDx (prostate cancer imaging)
 - ✓ **European Marketing Authorization Application** submitted (**April 2020**)
 - ✓ **U.S. FDA New Drug Application** submitted (**September 2020**)
 - ✓ **U.S. commercial distribution agreements** with **Cardinal Health** and **Pharmalogic**
 - ✓ Acquired a **licensed production facility** in Seneffe, Belgium
- **2021:** Phase III cancer therapeutics company with clear growth strategy
 - ✓ **China Grand Pharma** transaction delivers **A\$100M financial capacity for 2021 / 22**
 - ✓ Launch **ProstACT Phase III** of TLX591 (prostate cancer therapy)
 - ✓ Complete **ZIRCON Phase III trial** of TLX250-CDx (renal cancer imaging)
 - ✓ **Revenue generation** from TLX591-CDx (prostate cancer imaging)
 - ✓ Extend reach into **Asia** (China, Japan, Korea priority)

Diagnostics




Therapeutics




MTR: 'Radiation. Delivered'

1. Targeted radiation delivery



2. Systemic administration




3. See it...




PET scanner



TLX591-CDx ⁽¹⁾
(Prostate cancer)




4. ...Treat it



Enables precise **radiation delivery** to the cancer

TLX591
(Prostate cancer)



Notes: (1) Courtesy of Ammar Chaudhry MD, City of Hope, Duarte CA, USA.

Telix Pharmaceuticals Limited (ASX: TLX)

Telix's clinical pipeline in prostate, kidney, brain cancer



	Targeting Molecule	Cancer Cell Target	Radioactive Isotope	Phase I	Phase II	Phase III	Commercial
Prostate	Small molecule	PSMA (2)	⁶⁸ Ga	TLX591-CDx (⁶⁸ Ga-PSMA-11) NDA (US) & MAA (EU) filed			Imaging
	Antibody	PSMA	¹⁷⁷ Lu	TLX591 (¹⁷⁷ Lu-rosopitamab) PROSTACT			Therapy
Kidney	Antibody	CA IX (3)	⁸⁹ Zr	TLX250-CDx (⁸⁹ Zr-girentuximab) ZIRCON			Imaging
	Antibody	CA IX	¹⁷⁷ Lu	TLX250 (¹⁷⁷ Lu-girentuximab)			Therapy
Brain (1)	Small molecule	LAT1 (4)	¹²⁴ I	TLX101-CDx (Research use only)			Imaging
	Small molecule	LAT1	¹³¹ I	TLX101 (¹³¹ I-IPA) IPAX-1			Therapy

Shaded arrows indicate completion expectations in the next 12 months

Notes: (1) Glioblastoma multiforme (GBM)
 (2) PSMA = Prostate-specific membrane antigen 1
 (3) CA IX = Carbonic anhydrase IX
 (4) LAT1 = Large amino acid transporter 1

Telix: A phase III therapeutics company

Phase III ProstACT trial will evaluate TLX591 in mCRPC ⁽¹⁾



- Treatment for localised PCa depends on tumour characteristics, Gleason score, PSA and life expectancy
 - Active surveillance
 - Local therapy (prostatectomy or radiotherapy)
- Typically, men receive local therapy (prostatectomy and/or radiotherapy) and/or ADT ⁽²⁾
- If further progression occurs post-ADT, sequencing of therapy may comprise ⁽³⁾
 - First-line ADT / Abiraterone + taxane
 - **Second-line Enzalutamide (or equivalent) + taxane** ← **PROSTACT**
 - Third-line Taxane + palliation

PROSTACT

Eligible patients

- mCRPC
- Expressing PSMA (defined by **TLX591-CDx**)
- Progressed despite prior therapy with NAAD ⁽⁴⁾

TLX591 + standard of care therapy

Standard of care therapy alone

Notes: (1) mCRPC = Metastatic castration resistant prostate cancer

(2) ADT = Androgen Deprivation Therapy


(3) Simplified for illustrative purposes, does not include recent developments such as PARP inhibitors

(4) NAAD = Novel androgen axis drug

TLX591 confers significant advantages versus competition




Telix (TLX591)



- Targets PSMA⁽¹⁾
- Targeting agent: antibody
- Isotope: ¹⁷⁷Lu (lutetium)
- Slow / cumulative irradiation of tumour over ~5 days
- Off-target toxicity: haematologic
- Typical course of administration:
2 x 3.5 GBq (2 weeks total)

Competitor (PSMA-617)



- Targets PSMA
- Targeting agent: small molecule
- Isotope: ¹⁷⁷Lu (lutetium)
- Rapid urinary excretion, requires many doses to deliver effective tumour irradiation
- Off-target toxicity: exocrine glands, renal
- Typical course of administration:
4 – 6 x 7 GBq (6 months treatment)

Telix's cost of goods is ~20% of the competition, requires significantly fewer hospital visits and 'cold kit' format is highly suited to local (low cost) preparation

TLX591: For prostate cancer therapy the TAM is US\$4B



Annual incidence of prostate cancer in US/EU
(RoW excluded)

478,000 ⁽¹⁾



Patients with PSMA expressing mCRPC that has
progressed despite prior treatment with a NAAD eligible for
therapy with TLX591

43,000




TAM value

US\$4B ⁽²⁾

Notes: (1) GLOBOCAN 2018 reported incidence of prostate cancer in Telix's markets.
(2) US TAM value = USD1.8B, EU TAM value = USD2.2B.

The next 3 months...

A big quarter ahead... with major inflection points





Precision Oncology.
See it. Treat it.

telixpharma.com